Bright Minds Biosciences Announces Positive Topline Results From Phase 2 Clinical Trial Of BMB-101 In Patients With Absence Seizures And Developmental And Encephalopathic Epilepsies (DEE)
menafn|1/6/2026|depression
Share this article:
Share this article:





